Cognitive-behavioral analysis system of psychotherapy, drug, or their combination for persistent depressive disorder: Personalizing the treatment choice using individual participant data network metaregression

Psychotherapy and Psychosomatics

Volumn 87, Issue 3, 2018, Pages 140-153

  Furukawa, Toshi A ^a   Efthimiou, Orestis ^b   Weitz, Erica S ^c   Cipriani, Andrea ^d   Keller, Martin B ^e   Kocsis, James H ^f   Klein, Daniel N ^g   Michalak, Johannes ^h   Salanti, Georgia ^b   Cuijpers, Pim ^c   Schramm, Elisabeth ⁱ  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BROWN UNIVERSITY   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h UNIVERSITY OF WITTEN HERDECKE   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cognitive behavioral analysis system of psychotherapy; Persistent depressive disorder; Pharmacotherapy

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; MIRTAZAPINE; NEFAZODONE; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; COGNITIVE BEHAVIORAL ANALYSIS SYSTEM OF PSYCHOTHERAPY; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DSM-5; DSM-IV; FEMALE; HUMAN; INDEPENDENT VARIABLE; MAJOR DEPRESSION; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; DEPRESSION; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROCEDURES; PSYCHOTHERAPY; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTHERAPY;

EID: 85047904488     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000489227     Document Type: Article

References (65)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 5. Arlington, American Psychiatric Association, 2013.
2. Murphy JA, Byrne GJ: Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord 2012; 139: 172-180.
3. Furukawa TA, Kitamura T, Takahashi K: Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. Br J Psychiatry 2000; 177: 331-335.
4. Klein DN, Shankman SA, Rose S: Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry 2006; 163: 872-880.
5. Kocsis JH, Gelenberg AJ, Rothbaum B, Klein DN, Trivedi MH, Manber R, Keller MB, Howland R, Thase ME: Chronic forms of major depression are still undertreated in the 21st century: Systematic assessment of 801 patients presenting for treatment. J Affect Disord 2008; 110: 55-61.
6. Spijker J, van Straten A, Bockting CL, Meeuwissen JA, van Balkom AJ: Psychotherapy, antidepressants, their combination for chronic major depressive disorder: A systematic review. Can J Psychiatry 2013; 58: 386-392.
7. Kriston L, von Wolff A, Westphal A, Holzel LP, Harter M: Efficacy and acceptability of acute treatments for persistent depressive disorder: A network meta-analysis. Depress Anxiety 2014; 31: 621-630.
8. Von Wolff A, Holzel LP, Westphal A, Harter M, Kriston L: Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis. BMC Psychiatry 2012; 12: 61.
9. Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G: Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clin Psychol Rev 2010; 30: 51-62.
10. McCullough JP Jr: Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP). New York, Guilford Press 2000.
11. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, their combination for the treatment of chronic depression. N Engl J Med 2000; 342: 1462-1470.
12. Kocsis JH, Gelenberg AJ, Rothbaum BO, Klein DN, Trivedi MH, Manber R, Keller MB, Leon AC, Wisniewski SR, Arnow BA, Markowitz JC, Thase ME: Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: The REVAMP Trial. Arch Gen Psychiatry 2009; 66: 1178-1188.
13. Schramm E, Kriston L, Zobel I, Bailer J, Wambach K, Backenstrass M, Klein JP, Schoepf D, Schnell K, Gumz A, Bausch P, Fangmeier T, Meister R, Berger M, Hautzinger M, Harter M: Effect of disorder-specific vs nonspecific psychotherapy for chronic depression: A randomized clinical trial. JAMA Psychiatry 2017; 74: 233-242.
14. Horwitz RI, Hayes-Conroy A, Singer BH: Biology, social environment, personalized medicine. Psychother Psychosom 2017; 86: 5-10.
15. Collins FS, Varmus H: A new initiative on precision medicine. N Engl J Med 2015; 372: 793-795.
16. Horwitz RI, Singer BH, Makuch RW, Viscoli CM: Can treatment that is helpful on average be harmful to some patients A study of the conflicting information needs of clinical inquiry and drug regulation. J Clin Epidemiol 1996; 49: 395-400.
17. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR: Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 2011; 343:d5888.
18. Horwitz RI, Hayes-Conroy A, Caricchio R, Singer BH: From evidence based medicine to medicine based evidence. Am J Med 2017; 130: 1246-1250.
19. Petropoulou M, Nikolakopoulou A, Veroniki AA, Rios P, Vafaei A, Zarin W, Giannatsi M, Sullivan S, Tricco AC, Chaimani A, Egger M, Salanti G: Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. J Clin Epidemiol 2017; 82: 20-28.
20. Debray TP, Schuit E, Efthimiou O, Reitsma JB, Ioannidis JP, Salanti G, Moons KG; GetReal Workpackage: An overview of methods for network meta-analysis using individual participant data: When do benefits arise Stat Methods Med Res 2018; 27: 1351-1364.
21. Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG: Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data. Cochrane Database Syst Rev 2017; 12:CD011412.
22. Clarke MJ, Stewart LA: Obtaining data from randomised controlled trials: How much do we need for reliable and informative meta-analyses BMJ 1994; 309: 1007-1010.
23. Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S: Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72: 14-21.
24. Samara MT, Goldberg Y, Levine SZ, Furukawa TA, Geddes JR, Cipriani A, Davis JM, Leucht S: Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: A meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry 2017; 4: 859-867.
25. Furukawa TA, Weitz ES, Tanaka S, Hollon SD, Hofmann SG, Andersson G, Twisk J, DeRubeis RJ, Dimidjian S, Hegerl U, Mergl R, Jarrett RB, Vittengl JR, Watanabe N, Cuijpers P: Initial severity of depression and efficacy of cognitive-behavioural therapy: Individual-participant data meta-analysis of pill-placebo-controlled trials. Br J Psychiatry 2017; 210: 190-196.
26. Furukawa TA, Schramm E, Weitz ES, Salanti G, Efthimiou O, Michalak J, Watanabe N, Cipriani A, Keller MB, Kocsis JH, Klein DN, Cuijpers P: Cognitive-Behavioral Analysis System of Psychotherapy (CBASP), drug or their combination: Differential therapeutics for persistent depressive disorder: A study protocol of an individual participant data network meta-analysis. BMJ Open 2016; 6:e011769.
27. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015; 162: 777-784.
28. Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). 2011. www.cochrane-handbook.org.
29. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, Woo A, Trivedi MH: The Montgomery Asberg and the Hamilton ratings of depression: A comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601-611.
30. Lambert MJ: Maximizing psychotherapy outcome beyond evidence-based medicine. Psychother Psychosom 2017; 86: 80-89.
31. Fava GA, Guidi J, Rafanelli C, Rickels K: The clinical inadequacy of the placebo model and the development of an alternative conceptual framework. Psychother Psychosom 2017; 86: 332-340.
32. Kessler RC, van Loo HM, Wardenaar KJ, Bossarte RM, Brenner LA, Ebert DD, de Jonge P, Nierenberg AA, Rosellini AJ, Sampson NA, Schoevers RA, Wilcox MA, Zaslavsky AM: Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epidemiol Psychiatr Sci 2017; 26: 22-36.
33. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-771.
34. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 1996; 26: 477-486.
35. Efthimiou O, Debray TP, van Valkenhoef G, Trelle S, Panayidou K, Moons KG, Reitsma JB, Shang A, Salanti G; GetReal Methods Review Group: GetReal in network meta-analysis: A review of the methodology. Res Synth Methods 2016; 7: 236-263.
36. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR: Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res Synth Methods 2012; 3: 98-110.
37. R Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2016.
38. Lunn D, Spiegelhalter D, Thomas A, Best N: The BUGS project: Evolution, critique and future directions. Stat Med 2009; 28: 3049-3067.
39. Schramm E, Zobel I, Schoepf D, Fangmeier T, Schnell K, Walter H, Drost S, Schmidt P, Brakemeier EL, Berger M, Normann C: Cognitive behavioral analysis system of psychotherapy versus escitalopram in chronic major depression. Psychother Psychosom 2015; 84: 227-240.
40. Lizardi H, Klein DN, Ouimette PC, Riso LP, Anderson RL, Donaldson SK: Reports of the childhood home environment in early-onset dysthymia and episodic major depression. J Abnorm Psychol 1995; 104: 132-139.
41. Parker G, Roussos J, Hadzi-Pavlovic D, Mitchell P, Wilhelm K, Austin MP: The development of a refined measure of dysfunctional parenting and assessment of its relevance in patients with affective disorders. Psychol Med 1997; 27: 1193-1203.
42. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, Sapareto E, Ruggiero J: Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994; 151: 1132-1136.
43. Wingenfeld K, Spitzer C, Mensebach C, Grabe HJ, Hill A, Gast U, Schlosser N, Hopp H, Beblo T, Driessen M: The German version of the Childhood Trauma Questionnaire (CTQ): Preliminary psychometric properties (in German). Psychother Psychosom Med Psychol 2010; 60: 442-450.
44. NICE: Depression: Management of Depression in Primary and Secondary Care. London, National Institute for Clinical Excellence, 2004.
45. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583.
46. Huijbregts KM, Hoogendoorn A, Slottje P, van Balkom A, Batelaan NM: Long-term and short-term antidepressant use in general practice: Data from a large cohort in the Netherlands. Psychother Psychosom 2017; 86: 362-369.
47. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychother Psychosom 2016; 85: 270-288.
48. Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R: Effect of cognitive therapy with antidepressant medications versus antidepressants alone on the rate of recovery in major depressive disorder: A randomized clinical trial. JAMA Psychiatry 2014; 71: 1157-1164.
49. Thase ME, Greenhouse JB, Frank E, Reynolds CF 3rd, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ: Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54: 1009-1015.
50. Weitz ES, Hollon SD, Twisk J, van Straten A, Huibers MJ, David D, DeRubeis RJ, Dimidjian S, Dunlop BW, Cristea IA, Faramarzi M, Hegerl U, Jarrett RB, Kheirkhah F, Kennedy SH, Mergl R, Miranda J, Mohr DC, Rush AJ, Segal ZV, Siddique J, Simons AD, Vittengl JR, Cuijpers P: Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: An individual patient data meta-analysis. JAMA Psychiatry 2015; 72: 1102-1109.
51. Bagby RM, Quilty LC, Segal ZV, McBride CC, Kennedy SH, Costa PT: Personality and differential treatment response in major depression: A randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Can J Psychiatry 2008; 53: 361-370.
52. Frank E, Cassano GB, Rucci P, Thompson WK, Kraemer HC, Fagiolini A, Maggi L, Kupfer DJ, Shear MK, Houck PR, Calugi S, Grochocinski VJ, Scocco P, Buttenfield J, Forgione RN: Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011; 41: 151-162.
53. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R: Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 2009; 77: 775-787.
54. Cuijpers P, Reynolds CF 3rd, Donker T, Li J, Andersson G, Beekman A: Personalized treatment of adult depression: Medication, psychotherapy, or both A systematic review. Depress Anxiety 2012; 29: 855-864.
55. Nanni V, Uher R, Danese A: Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. Am J Psychiatry 2012; 169: 141-151.
56. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003; 100: 14293-14296.
57. Egger M, Moons KG, Fletcher C: GetReal: From efficacy in clinical trials to relative effectiveness in the real world. Res Synth Methods 2016; 7: 278-281.
58. Efthimiou O, Mavridis D, Debray TP, Samara M, Belger M, Siontis GC, Leucht S, Salanti G; GetReal Work Package: Combining randomized and non-randomized evidence in network meta-analysis. Stat Med 2017; 36: 1210-1226.
59. Cipriani A, Higgins JP, Geddes JR, Salanti G: Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013; 159: 130-137.
60. Salanti G: Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012; 3: 80-97.
61. Nevitt SJ, Marson AG, Davie B, Reynolds S, Williams L, Smith CT: Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: Systematic review. BMJ 2017; 357:j1390.
62. Wallace ML, Frank E, Kraemer HC: A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 2013; 70: 1241-1247.
63. DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L: The Personalized Advantage Index: Translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One 2014; 9:e83875.
64. Collins GS, Reitsma JB, Altman DG, Moons KG: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med 2015; 162: 55-63.
65. Vandvik PO, Brignardello-Petersen R, Guyatt GH: Living cumulative network meta-analysis to reduce waste in research: A paradigmatic shift for systematic reviews BMC Med 2016; 14: 59.